Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Open access
Pedrazzoli, Paolo, Farris, Antonio, Del Prete, Salvatore, Del Gaizo, Filomena, Ferrari, Daris, Bianchessi, Clara, Colucci, Giuseppe, Desogus, Alberto, Gamucci, Teresa, Pappalardo, Alessandro, Fornarini, Giuseppe, Pozzi, Paola, Fabi, Alessandra, Labianca, Roberto, Di Costanzo, Francesco, Secondino, Simona, Crucitta, Enrico, Apolloni, Federica, Del Santo, Antonio, Siena, Salvatore·2008·Journal of Clinical Oncology

Abstract

Purpose: Unresponsiveness to erythropoiesis-stimulating agents, occurring in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia. We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin. Patients and Methods: Between December 2004 and February 2006, 149 patients with lung, gynecologic, breast, and colorectal cancers and ≥ 12 weeks of planned chemotherapy were enrolled from 33 institutions. Patients were required to have hemoglobin ≤ 11 g/L and no absolute or functional iron deficiency. All patients received darbepoetin 150 μg subcutaneously once weekly for 12 weeks and were randomly assigned to sodium ferric gluconate 125 mg intravenously (IV) weekly for the first 6 weeks (n = 73) or no iron (n = 76). Primary end point of the study was the percentage of patients achieving hematopoietic response (hemoglobin ≥ 12 g/dL or ≥ 2 g/dL increase). Results: Hematopoietic response by intention-to-treat analysis was 76.7% (95%CI, 65.4% to 85.8%) in the darbepoetin/iron group and 61.8% (95%CI, 50.0% to 72.7%) in the darbepoetin group (P = .0495). Among patients fulfilling eligibility criteria and having received at least four darbepoetin administrations, hematopoietic responses in the darbepoetin/iron group (n = 53) and in the darbepoetin-only group (n = 50) were 92.5% (95% CI, 81.8% to 97.9%) and 70% (95% CI, 55.4% to 82.1%), respectively (P = .0033). Increase of hemoglobin during treatment period showed a time profile favoring darbepoetin/iron with statistically significant effect from week 5 on. The safety profile was comparable in the two arms. Conclusion: In patients with chemotherapy-related anemia and no iron deficiency, IV iron supplementation significantly reduces treatment failures to darbepoetin without additional toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.12.2051

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 168

Metadata

Authors
Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Bianchessi, C., Colucci, G., Desogus, A., Gamucci, T., Pappalardo, A., Fornarini, G., Pozzi, P., Fabi, A., Labianca, R., Di Costanzo, F., Secondino, S., Crucitta, E., Apolloni, F., Del Santo, A., & Siena, S.
Venue
Journal of Clinical Oncology
Published
2008-04-01
Volume
26
Issue
10
Pages
1619-1625
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2165848930
Cited by
168
References
1
FWCI
13.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa. https://app.cochat.ai/papers/10.1200/jco.2007.12.2051
The paper
Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Bianchessi, C., Colucci, G., Desogus, A., Gamucci, T., Pappalardo, A., Fornarini, G., Pozzi, P., Fabi, A., Labianca, R., Di Costanzo, F., Secondino, S., Crucitta, E., Apolloni, F., Del Santo, A., & Siena, S. (2008). Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.12.2051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.